Growth hormone secretagogue
GHRP-2
A synthetic growth hormone-releasing hexapeptide, INN pralmorelin, with no FDA-approved drug product. It is on FDA's active 503B Category 2 table for injectable and nasal routes, and is named on the WADA Prohibited List.
Why people are interested in GHRP-2
A synthetic growth hormone-releasing hexapeptide, INN pralmorelin, with no FDA-approved drug product. It is on FDA's active 503B Category 2 table for injectable and nasal routes, and is named on the WADA Prohibited List.
- Growth hormone secretagogues— a research-category classification, not a claimed use
Where the interest comes from differs by compound: published research, an approved use, clinical discussion, community discussion and vendor claims are different things. This page keeps them apart — the sections below say which kind of source supports each statement.
Quick facts
- Molecular weight
- 818.0 g/mol
- Sequence length
- 35 chars
- CAS number
- 158861-67-7
- PubChem CID
- 6918245
0 evidence records indexed · 0 clinical trials · last reviewed 15 September 2026
Research at a glance
No evidence records in this file yet.
What has actually been studied
What is still unknown
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Preparation and handling
Lyophilized peptides ship as powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific. Therapept’s preparation guides explain the vocabulary and the arithmetic; the product’s own documentation states its requirements.
United States regulatory status
FDA compounding Category 2
- No approved drug product exists in Drugs@FDA.
- Listed by FDA as “Growth hormone releasing peptide-2 (GHRP-2)” on the active Category 2 table for 503B compounding, for injectable and nasal routes of administration, added 29 September 2023.
- FDA's published concerns include immunogenicity risk from aggregation and peptide-related impurities, the added characterisation complexity of an unnatural amino acid, and reports of serious adverse events in patients who received GHRP-2.
- No registered studies were returned by ClinicalTrials.gov for the intervention name GHRP-2 at review.
Anti-doping status
Named at S2.2.4 among GH-releasing peptides, as “GHRP-2 (pralmorelin)”. Prohibited at all times.
Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.
Technical identity
- Compound class
- Growth hormone secretagogue; synthetic hexapeptide containing D-amino acids and 2-naphthylalanine
- Sequence
- D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
- Molecular formula
- C45H55N9O6
- Molecular weight
- 818.0 g/mol
- CAS number
- 158861-67-7
- PubChem CID
- 6918245
- Research categories
- Growth hormone secretagogues
Sources
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built